Epilepsy is one of the most common chronic neurological disorders, and it affects approximately 68 million people worldwide [1]. One-third of patients with epilepsy require more effective antiseizure medications (ASMs) because their epileptic seizures remain uncontrolled with the currently available medical treatment, which leads to significant morbidity and imposes a heavy healthcare-related economic burden [2]. Consequently, there is a need to identify the risk factors associated with drug-resistant epilepsy (DRE) and develop adjuvant therapies.
25
JUL
JUL
0